¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Toxic effect of unspecified substance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • detergent effect
    ¼¼Ã´È¿°ú, Á¤È­È¿°ú
  • deterministic effect
    È®Á¤ÀûÈ¿°ú
  • diabetogenic effect
    ´ç´¢º´À¯¹ßÈ¿°ú
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • effect
    È¿°ú
  • greenhouse effect
    ¿Â½ÇÈ¿°ú
  • healthy worker effect
    °Ç°­±Ù·ÎÀÚÈ¿°ú
  • halo effect
    ´Þ¹«¸®È¿°ú
  • isotopic effect
    µ¿À§¿ø¼ÒÈ¿°ú
  • inflow effect
    À¯ÀÔÈ¿°ú
  • inotropic effect
    ¼öÃàÃËÁøÈ¿°ú
  • late effect
    ¸¸±âÈ¿°ú
  • latitude effect
    À§µµÈ¿°ú
  • masking effect
    ÀºÆóÈ¿°ú
  • mass effect
    µ¢ÀÌÈ¿°ú, Á¾±«È¿°ú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • depressor substance
    °¨¾Ð¹°Áú, ³»¸²¹°Áú
  • endobiotic substance
    ³»¼º¹°Áú
  • enzyme trace substance theory
    È¿¼ÒÈçÀû¹°¼³
  • erythrocyte sensitizing substance
    ÀûÇ÷±¸¹Î°¨¹°Áú
  • exophthalmos-producing substance
    ´«µ¹ÃâÀ¯¹ß¹°Áú
  • ferromagnetic substance
    ¼¾ÀÚ¼º¹°Áú, °­ÀÚ¼ºÃ¼
  • fibrinoid substance
    ¼¶À¯¼Ò¼º¹°Áú
  • fundamental substance
    ¹«ÇüÁú
  • gap substance
    »çÀ̹°Áú
  • gelatinous substance
    ¾Æ±³Áú
  • goitrogenic substance
    ¹æÆÐ»ùÁ¾À¯¹ß¹°Áú, °©»ó»ùÁ¾À¯¹ß¹°Áú
  • gray substance
    ȸ»öÁú
  • ground substance
    ¹ÙÅÁÁú
  • heparinoid substance
    ÇìÆÄ¸°¼º¹°Áú
  • heterogeneous substance
    ºÒ±ÕÁúü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Stiles-Crawford effect
    ½ºÅ¸ÀϽº-Å©·ÎÆ÷µåÈ¿°ú
  • T1 shortening effect
    T1 ´ÜÃà È¿°ú
  • T2 shortening effect
    T2 ´ÜÃà È¿°ú
  • Tyndall effect
    ƾ´ÞÈ¿°ú
  • additive effect
    ºÎ°¡È¿°ú
  • additive effect
    »ó°¡È¿°ú (ßÓÊ¥üùÍý)
  • adverse effect
    ¿ªÈ¿°ú(æ½üùÍý).¾à¸®À¯ÇØÈ¿°ú.
  • adverse effect
    ¿ªÈ¿°ú, À¯ÇØÈ¿°ú
  • air barrier effect
    °ø±â¸·È¿°ú(ÍöѨدüùÍý).
  • air gap effect
    °ø±â °£°Ý È¿°ú
  • allogeneic effect
    µ¿Á¾ÀÌÇüÈ¿°ú
  • analgesic effect
    ÁøÅëÈ¿°ú.
  • antagonistic effect
    ±æÇ×È¿°ú
  • anticoagulant effect
    Ç×ÀÀ°íÈ¿°ú.
  • anticurare effect
    Ç×Å¥¶ó·¹ÀÛ¿ë.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • toxic granule
    µ¶¼º°ú¸³(Ô¸àõΨí£)
  • toxic hepatitis
    µ¶¼º°£¿°(Ô¸àõÊÜæú)
  • toxic idiopathy
    Áßµ¶¼ºÆ¯¹ßº´(¡­÷åÛ¡Ü»)
  • toxic injury, cellular
    µ¶¼º »óÇØ(¼Õ»ó), ¼¼Æ÷¼º
  • toxic lesion
    Áßµ¶¼ºº´º¯(ñéÔ¸àõܻܨ)
  • toxic leukocytosis
    Áßµ¶¼º¹éÇ÷±¸Áõ°¡Áõ(¡­ÛÜúìϹñòÊ¥ñø)
  • toxic megacolon
    Áßµ¶¼º°Å´ë°áÀåÁõ(¡­ËÝÓÞÌ¿íóñø).
  • toxic megacolon
    µ¶¼º°Å´ë°áÀåÁõ(¡­ËÝÓÞÌ¿íóñø)
  • toxic myelopathy
  • toxic myocarditis
    Áßµ¶¼º½É±Ù¿°(¡­ãýÐÉæú)
  • toxic necrosis
    Áßµ¶¼º±«»ç(¡­ÎÕÞÝ)
  • toxic nephropathy
    Áßµ¶¼º ½Åº´Áõ
  • toxic nephrosclerosis
    Áßµ¶¼º½Å°æÈ­Áõ(¡­ãìÌãûùñø)
  • toxic nephrosis
    Áßµ¶¼º½ÅÁõ(¡­ãìñø)
  • toxic neuritis
    Áßµ¶¼º½Å°æ¿°(¡­ãêÌèæú).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • primary charge effect
    ÀÏÂ÷ ÀüÇÏÈ¿°ú(ìéó­ï³ùÃüùÍý)
  • primary isotope effect
    ÀÏÂ÷ µ¿À§¿ø¼Ò È¿°ú(ìéó­ÔÒêÈêªáÈüùÍý)
  • propinquit effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • proximity effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • Raman effect
    ¶ó¸¸ È¿°ú(üùÍý)
  • relaxation effect
    ÀÌ¿Ï È¿°ú(ì¬èÐüùÍý)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • sparing effect
    ¿¹ºñÈ¿°ú(çãÝáüùÍý)
  • spreading position effect
    ÆÛÁü À§Ä¡ È¿°ú(êÈöÇüùÍý)
  • Stark effect
    ½ºÅ¸Å© È¿°ú(üùÍý)
  • thyrotoxic effect
    °©»ó¼±Áßµ¶ È¿°ú (Ë£ßÒàÍñéÔ¸üùÍý)
  • time factor effect
    ½Ã°£ÀÎÀÚ È¿°ú (ãÁÊàì×í­üùÍý)
  • trans effect
    Æ®¶õ½º È¿°ú(üùÍý)
  • Tyndall effect
    ƾ´Þ È¿°ú(üùÍý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
HWE healthy worker effect; hot water extract
IGFET insulated gate field effect transistor
ITE insufficient therapeutic effect; in the ear [hearing aid]; in-training examination; intrapulmonary i...
JFET junction field effect transistor
LEL lower explosive limit; lowest effect level
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DLS Digitalis-like substance
DLIS Digoxin-like immunoreactive substance
EDLS Endogenous digitalis-like substance
HSS Hepatic Stimulatory Substance
I-SP Immunoreactive substance P
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clasp knife effect
    Á¢´Â Ä® È¿°ú
  • cytopathogenic effect
    ¼¼Æ÷ º¯¼º Çö»ó, ¼¼Æ÷ º´º¯ È¿°ú
  • Deelman`s effect
    µ¨¸¸ È¿°ú
  • detergent effect
    Á¤È­ ÀÛ¿ë
  • domino effect
    µµ¹Ì³ë È¿°ú
  • Donnan effect
    µµ³­ È¿°ú
  • Doppler effect
    µµÇ÷¯ È¿°ú, Doppler È¿°ú
    1. ±Ù¿øÁö¿¡ ´ëÇÑ ¼ö½ÅÁöÀÇ »ó´ëÀûÀÎ ¿îµ¿À¸·ÎºÎÅÍ ¾ß±âµÇ´Â Á֯ļöÀÇ ¸í¹éÇÑ º¯È­. 2. ¾î¶² ¹°Ã¼°¡ ¿îµ¿ »óÅ¿¡ ÀÖÀ» ¶§ ³ªÅ¸³ª´Â ¹ÝÇâµÇ´Â ¹æ»ç¼±¿¡¼­ Áøµ¿¼öÀÇ º¯È­´Â µµÇ÷¯ È¿°úÀÇ °á°úÀÌ´Ù. ¹æ»ç¼±ÀÇ ±Ù¿øÀ¸·ÎºÎÅÍ ¶³¾îÁø ¹°Ã¼ÀÇ ¿îµ¿Àº Á¤Áö »óÅÂÀÇ ¹°Ã¼¿¡ ºñ±³ÇØ º¼ ¶§ ´õ ³·Àº Áøµ¿¼öÀÇ ¹ÝÇâÀ» ÀÏÀ¸Å³ °ÍÀÌ´Ù. ¹æ»ç¼±ÀÇ ±Ù¿øÀ» ÇâÇÑ ¿îµ¿Àº ´õ ³ôÀº Áøµ¿¼ö¸¦ ÀÏÀ¸Å²´Ù.
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • double effect
    ÀÌÁß È¿°ú
  • drug side effect
    ºÎÀÛ¿ë
  • efferent effect
    ¿ø½É È¿°ú
  • entry slice effect
    À¯ÀÔ ´Ü¸é È¿°ú
  • first pass effect
    ÀÏÂ÷ Åë°ú È¿°ú
  • focus effect
    ÃÐÁ¡ È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
muscular substance of prostate The smooth muscle in the stroma of the prostate.
Synonym: substantia muscularis prostatae, musculus prostaticus.
(05 Mar 2000)
controlled substance A substance subject to the Controlled Substances Act (1970), which regulates the prescribing and dispensing, as well as the manufacturing, storage, sale, or distribution of substance's assigned to five schedules according to their 1) potential for or evidence of abuse, 2) potential for psychic or physiologic dependence, 3) contributing a public health risk, 4) harmful pharmacologic effect, or 5) role as a precursor of other controlled substance's.
(05 Mar 2000)
cortical substance The superficial thin layer of compact bone.
Synonym: substantia corticalis, cortical substance.
(05 Mar 2000)
posterior perforated substance The bottom of the interpeduncular fossa at the base of the midbrain, extending from the anterior border of the pons forward to the mamillary bodies, and containing numerous openings for the passage of perforating branches of the posterior cerebral arteries.
Synonym: substantia perforata posterior, locus perforatus posticus, Malacarne's space.
(05 Mar 2000)
pressor substance One of several products of intestinal putrefaction believed to cause functional hypertension when absorbed, any alkaline substance that raises blood pressure.
Synonym: pressor amine, pressor substance.
(05 Mar 2000)
proper substance See: substantia propria of cornea, substantia propria membranae tympani, substantia propria sclerae.
(05 Mar 2000)
schwann's white substance <anatomy> The substance of the medullary sheath.
Source: Websters Dictionary
(01 Mar 1998)
psychoses, substance-induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance.
(12 Dec 1998)
sensitizing substance Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis.
Synonym: CF antibody, sensitizing substance.
(05 Mar 2000)
h substance <haematology> A polysaccharide precursor molecule which is used to make the antigens on the surface of human blood cells that are classified in the ABO blood group system.
(09 Oct 1997)
slow-reacting substance Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules.
Compare: peptidyl leukotrienes.
Synonym: slow-reacting factor of anaphylaxis.
(05 Mar 2000)
slow reacting substance of anaphylaxis <immunology> Potent bronchoconstrictor and inflammatory agent released by mast cells, an important mediator of allergic bronchial asthma.
A mixture of three leukotrienes (LTC4 mainly, LTD4 and LTE4)
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
specific capsular substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
spongy substance Bone in which the spicules or trabeculae form a three-dimensional latticework (cancellus) with the interstices filled with embryonal connective tissue or bone marrow.
Synonym: substantia trabecularis, cancellous bone, spongy bone, spongy substance, trabecular bone.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á